Momelotinib (LM1149; CYT387; CYT11387)

Description: Momelotinib (formerly CYT-387; CYT-11387; LM-1149), an aminopyrimidine analog, is a novel, potent and ATP-competitive inhibitor of Janus kinases (JAK1/2) with potential antitumor and anti-inflammatory activity. It inhibits JAK1/2 with IC50s of 11 nM/18 nM, and shows ca.10-fold selectivity for JAK1/2 over JAK3. CYT 387 is currently undergoing Phase I/II clinical trials for treating myelofibrosis. Momelotinib shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy. It was discovered by high-throughput enzyme and cell-based screening along with the optimization using structure-guided medicinal chemistry.

References: Leukemia. 2009 Aug; 23(8):1441-5; Leukemia. 2011 Dec; 25(12):1891-9; Blood. 2010 Jun 24; 115(25):5232-40.

Related CAS: 1056636-07-7 (Momelotinib Mesylate); 1056636-06-6 (Momelotinib sulfate); 1380317-28-1 (HCl); 1056634-68-4 (free base)

LM-1149 , CYT-11387; LM 1149 , CYT 11387; LM1149 , CYT11387; CYT-387; Momelotinib; Momelotinib free base; CYT387; CYT 387

Chemical Name: N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide.

InChi Key: ZVHNDZWQTBEVRY-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9, 11H, 12-16H2, (H, 25, 30)(H, 26, 27, 28)

SMILES Code: O=C(NCC#N)C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1